-
Mashup Score: 1Adjuvant versus salvage radiotherapy: debates will be reignited - 2 hour(s) ago
Dr. Parker and colleagues report in the current issue of Annals of Oncology the updated results of the RADICALS-RT randomized trial evaluating the superiority of adjuvant radiotherapy (ART) versus early salvage radiotherapy (eSRT).1 Based on the similar biochemical control results reported after a median follow-up of 4.9 years, eSRT was deemed by many as the standard of care for predominately clinically intermediate-risk men post-radical prostatectomy (RP). 2
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0ASTCT Talks: Beyond Remission: Navigating the Late Effects of Pediatric CAR T-Cell Therapy - 2 hour(s) ago
In this episode “ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children’s Research Hospital, dive into the pioneering realm of CAR T-cell therapy and…
Source: www.astct.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 3 hour(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja Wobus, PhD, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the findings of preclinical studies investigating tasquinimod, a small molecular oral inhibitor of S100A9, for mitigating the effects of the pathological inflammasome activation in the bone microenvironment seen in MDS. The agent was studied in vitro in mesenchymal stromal cells (MSCs) and in vivo in transgenic murine models. Dr Wobus highlights that the findings provide the first evidence that tasquinimod may have potential benefits for cytopenic patients with lower-risk MDS. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treat
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma - 8 hour(s) ago
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs prostate-only …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
The accompanying Editorial - Adjuvant versus salvage radiotherapy: debates will be reignited https://t.co/M2jNARXYiq https://t.co/knT4jHTYpv